ImmuCell Corporation (NASDAQ:ICCC) and IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|IntelliPharmaCeutics International Inc.||N/A||0.00||N/A||-3.26||0.00|
We can see in table 1 the earnings per share, top-line revenue and valuation of ImmuCell Corporation and IntelliPharmaCeutics International Inc.
Table 2 provides the return on equity, net margins and return on assets of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|IntelliPharmaCeutics International Inc.||0.00%||0%||0%|
Risk and Volatility
A beta of 1.25 shows that ImmuCell Corporation is 25.00% more volatile than Standard & Poor’s 500. IntelliPharmaCeutics International Inc.’s 2.19 beta is the reason why it is 119.00% more volatile than Standard & Poor’s 500.
Institutional and Insider Ownership
Roughly 14.1% of ImmuCell Corporation shares are held by institutional investors while 0.5% of IntelliPharmaCeutics International Inc. are owned by institutional investors. Insiders held 6.3% of ImmuCell Corporation shares. On the other hand, insiders held about 56.5% of IntelliPharmaCeutics International Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|IntelliPharmaCeutics International Inc.||-15.57%||-12.12%||-18.42%||-87.94%||-95.32%||19.88%|
For the past year ImmuCell Corporation had bearish trend while IntelliPharmaCeutics International Inc. had bullish trend.
IntelliPharmaCeutics International Inc. beats ImmuCell Corporation on 5 of the 9 factors.
ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. It also develops Rexista Oxycodone, an abuse and alcohol-deterrent controlled-release oral formulation for the relief of pain; Regabatin XR and Lyrica pregabalin extended-release capsules for the management of neuropathic pain; Effexor XR, an extended-release capsule for oral administration to treat depression; and Protonix, a delayed-release capsule for oral administration to treat gastroesophageal reflux disease. In addition, the company offers Glucophage XR, an oral antihyperglycemia drug to treat type 2 diabetes; Seroquel XR, an oral psychotropic agent for the treatment of schizophrenia, bipolar disorder, and major depressive disorder; Lamictal XR, an anticonvulsant drug to terat epilepsy; Keppra XR, an antiepileptic drug for the treatment of partial onset seizures in patients with epilepsy; and Pristiq, a selective serotonin and norepinephrine reuptake inhibitor to treat major depressive disorder. Further, it provides Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Intellipharmaceutics International Inc. has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.